Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Everest Starts China Phase III Trial of Ulcerative Colitis Treatment

publication date: Nov 15, 2019

Everest Medicines, a New York biopharma that develops novel drugs for Greater China and Asia, has dosed the first patient in a China Phase III trial of etrasimod, a novel treatment for ulcerative colitis. In 2017, Everest in-licensed greater China rights to etrasimod from Arena Pharma of San Diego in a $224 million two-drug agreement. Everest was backed with $50 million in initial financing led by China's C-Bridge Capital and set up as a C-Bridge incubator platform for bringing novel drugs to China. More details....

Stock Symbol: (NSDQ: ARNA)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China